Payment overview · 2025
General Payments
$1,114.24
61 reported records · 16 companies
Healthcare provider profile · identity verified
Dominic M Sciamanda, DO
Allopathic & Osteopathic Physicians|Neuromusculoskeletal Medicine & OMM · ERIE, PA · NPI 1336107887
Verified facts
What the public records show
CMS Open Payments records show Dominic M Sciamanda, DO received $1,114.24 in general payments during 2025 across 61 reported records.
Lilly USA, LLC accounted for 13.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 245 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 245 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $153.60 | 13.8% | 10 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $123.72 | 11.1% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $104.55 | 9.4% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $102.01 | 9.2% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $99.05 | 8.9% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $80.00 | 7.2% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $71.90 | 6.5% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $70.15 | 6.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $65.92 | 5.9% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $60.27 | 5.4% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $50.29 | 4.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.06 | 4.5% | 3 | 2025 |
| Fisher & Paykel Healthcare Inc | Unresolved — no canonical attribution shown | $26.80 | 2.4% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.85 | 2.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.70 | 1.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.37 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,114.24 | 61 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $123.72 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $108.45 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $104.55 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $102.01 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $80.00 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $77.17 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $77.17 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $70.15 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $65.92 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $60.27 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $55.29 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $54.71 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $50.29 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $46.76 | 3 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $39.88 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $36.46 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.99 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $34.99 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $30.81 | 2 | 2025 |
Source payment records
|
|||||
| FISHER & PAYKEL HEALTHCARE Normalized: fisher paykel healthcare |
Device | Fisher & Paykel Healthcare Inc | $26.80 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 245 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 91 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 90 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | 19 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
245 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
90 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
245 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 566 | 105 |
| Pantoprazole Sodium | Pantoprazole Sodium | 459 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 397 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 283 | 63 |
| Eliquis | Apixaban | 245 | 32 |
| Furosemide | Furosemide | 226 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 215 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 196 | 39 |
| Lisinopril | Lisinopril | 189 | 45 |
| Gabapentin | Gabapentin | 161 | 30 |
| Losartan Potassium | Losartan Potassium | 161 | 35 |
| Sertraline Hcl | Sertraline Hcl | 160 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 156 | 30 |
| Xarelto | Rivaroxaban | 155 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 152 | 32 |
| Metformin Hcl | Metformin Hcl | 136 | 33 |
| Potassium Chloride | Potassium Chloride | 126 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 111 | 33 |
| Buspirone Hcl | Buspirone Hcl | 107 | 25 |
| Famotidine | Famotidine | 106 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 102 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 95 | 23 |
| Jardiance | Empagliflozin | 91 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 90 | 21 |
| Bumetanide | Bumetanide | 87 | 21 |
| Levetiracetam | Levetiracetam | 85 | 13 |
| Omeprazole | Omeprazole | 85 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 84 | 14 |
| Donepezil Hcl | Donepezil Hcl | 82 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 17 |
| Nystatin | Nystatin | 82 | 24 |
| Warfarin Sodium | Warfarin Sodium | 78 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 21 |
| Mirtazapine | Mirtazapine | 75 | 14 |
| Montelukast Sodium | Montelukast Sodium | 75 | 18 |
| Tramadol Hcl | Tramadol Hcl | 75 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 70 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 69 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 16 |
| Prednisone | Prednisone | 67 | 32 |
| Trazodone Hcl | Trazodone Hcl | 67 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 64 | 11 |
| Simvastatin | Simvastatin | 64 | 15 |
| Trulicity | Dulaglutide | 63 | suppressed |
| Allopurinol | Allopurinol | 59 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 55 | suppressed |
| Latanoprost | Latanoprost | 55 | suppressed |
| Baclofen | Baclofen | 52 | 13 |
| Spironolactone | Spironolactone | 52 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 50 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 50 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 16 |
| Risperidone | Risperidone | 46 | suppressed |
| Memantine Hcl | Memantine Hcl | 45 | 12 |
| Tradjenta | Linagliptin | 44 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | suppressed |
| Meloxicam | Meloxicam | 41 | 14 |
| Ozempic | Semaglutide | 41 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 40 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 38 | suppressed |
| Entresto | Sacubitril/Valsartan | 38 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | suppressed |
| Olanzapine | Olanzapine | 37 | suppressed |
| Ranolazine Er | Ranolazine | 37 | suppressed |
| Carvedilol | Carvedilol | 36 | suppressed |
| Pregabalin | Pregabalin | 35 | 11 |
| Lorazepam | Lorazepam | 34 | 19 |
| Divalproex Sodium | Divalproex Sodium | 33 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 14 |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 31 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 19 |
| Cephalexin | Cephalexin | 28 | 14 |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Nystop | Nystatin | 28 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Azithromycin | Azithromycin | 25 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Lactulose | Lactulose | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Perphenazine | Perphenazine | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 20 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Verapamil Sr | Verapamil Hcl | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Insulin Lispro | Insulin Lispro | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Lacosamide | Lacosamide | 17 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Drizalma Sprinkle | Duloxetine Hcl | 16 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 16 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Methadone Hcl | Methadone Hcl | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 14 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Secuado | Asenapine | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Copaxone | Glatiramer Acetate | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,114.24 · 61 records | Lilly USA, LLC | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, EVENITY, FISHER & PAYKEL HEALTHCARE, JARDIANCE, LOKELMA, MOUNJARO, NEXLETOL, NURTEC ODT, OFEV, Ozempic, PROLIA, RECORLEV, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error